<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-α-inducible protein-2 (TNFAIP2) is a protein upregulated in cultured cells treated with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor α (TNF), but its expression in <z:mpath ids='MPATH_458'>normal</z:mpath> and neoplastic tissues remains largely unknown </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we use standard immunohistochemical techniques to demonstrate that TNFAIP2 is normally expressed by follicular dendritic cells, interdigitating dendritic cells, and macrophages but not by lymphoid cells in secondary lymphoid tissues </plain></SENT>
<SENT sid="2" pm="."><plain>Consistent with this expression pattern, we found strong TNFAIP2 staining of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in 4 of 4 cases (100%) of follicular dendritic cell <z:hpo ids='HP_0100242'>sarcoma</z:hpo> and in 3 of 3 cases (100%) of histiocytic <z:hpo ids='HP_0100242'>sarcoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Although TNFAIP2 is not expressed by the small and intermediate-sized neoplastic B cells comprising follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, or marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, we observed strong TNFAIP2 staining of the large, neoplastic cells in 31 of 31 cases (100%) of classical Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, in 12 of 12 cases (100%) of nodular lymphocyte-predominant Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and in 27 of 31 cases (87%) of primary mediastinal (thymic) large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In contrast, TNFAIP2 was expressed by malignant cells in only 2 of 45 cases (4%) of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, not otherwise specified, in 2 of 18 cases (11%) of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and in 1 of 19 cases (5%) of anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Further analysis indicates that TNFAIP2, as a single diagnostic marker, is more sensitive (sensitivity=87%) and specific (specificity=96%) than TRAF1, nuclear cRel, or CD23 for distinguishing the malignant B cells of primary mediastinal (thymic) large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> from those of its morphologic and immunophenotypic mimic, diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, not otherwise specified </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, TNFAIP2 may serve as a useful new marker of dendritic and histiocytic <z:hpo ids='HP_0100242'>sarcomas</z:hpo>, the aberrant expression of which in the malignant cells of classical Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and primary mediastinal (thymic) large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> serves to distinguish these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from other large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> in routine clinical practice </plain></SENT>
</text></document>